Imaging proliferation of 18F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 8, 2012, Pages 1289-1296

  Yang, Wenfeng ^a   Zhang, Yongming ^a   Fu, Zheng ^a   Sun, Xiaorong ^a   Mu, Dianbin ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

18F FLT; CD105; CD34; Microvessel density; Non small cell lung cancer; PET CT

Indexed keywords

3' FLUOROTHYMIDINE F 18; CD105 MONOCLONAL ANTIBODY; CD31 ANTIGEN; CD31 MONOCLONAL ANTIBODY; CD34 ANTIBODY; CD34 ANTIGEN; ENDOGLIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; LEUKOCYTE ANTIGEN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROVESSEL DENSITY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION; CELL PROLIFERATION; CLINICAL TRIAL; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; MICROVASCULATURE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS;

EID: 84865477256     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2126-8     Document Type: Article

References (39)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-64. (Pubitemid 26272076)
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-8.
3. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol. 1998;184:119-22.
4. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, et al. Vascular endothelial growth factor, plateletderived endothelial cell growth factor and angiogenesis in nonsmall-cell lung cancer. Br J Cancer. 2000;82:1427-32. (Pubitemid 30175909)
5. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33:125-32.
6. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, et al. Differentiation and definition of vasculartargeted therapies. Clin Cancer Res. 2005;11:416-20.
7. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-20. (Pubitemid 37297757)
8. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ,Han J, et al.Non-small cell lung cancer: prospective comparison ofintegrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011-9. (Pubitemid 41170866)
9. Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer. 2008;61:35-43.
10. Mier W, Haberkorn U, Eisenhut M. [18F]FLT: portrait of a proliferation marker. Eur J Nucl Med Mol Imaging. 2002;29:165-9. (Pubitemid 34143447)
11. VesselleH,Grierson J,MuziM, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18) F]FLT) as a proliferation imaging tracer in humans: correlation of [(18) F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-23. (Pubitemid 35340704)
12. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62:3331-4. (Pubitemid 34651372)
13. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049-55. (Pubitemid 351551115)
14. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706-14. (Pubitemid 47357522)
15. Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008;35:236-45.
16. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001;7:3410-5. (Pubitemid 33069974)
17. Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med. 2008;49:186-94. (Pubitemid 351225655)
18. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-7. (Pubitemid 34988769)
19. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-22. (Pubitemid 30054364)
20. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018-25. (Pubitemid 40128768)
21. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875-87. (Pubitemid 23004615)
22. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis -correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
23. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002;87:694-701. (Pubitemid 35178743)
24. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996;32A:2474-84.
25. Guo J, Higashi K, Ueda Y, Oguchi M, Takegami T, Toga H, et al. Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med. 2006;47:419-25. (Pubitemid 46768483)
26. Giatromanolaki A, Koukourakis MI, Theodossiou D, Barbatis K, O'Byrne K, Harris AL, et al. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res. 1997;3(12 Pt 1):2485-92. (Pubitemid 28133172)
27. Kumar P, Wang JM, Bernabeu C. CD105 and angiogenesis. J Pathol. 1996;178:363-6.
28. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856-61. (Pubitemid 29086739)
29. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer. 1999;81:568-72. (Pubitemid 29203054)
30. Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate. 2002;51:268-75. (Pubitemid 34556377)
31. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34. (Pubitemid 36910021)
32. Pennell NA, Lynch Jr TJ. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009;14:399-411.
33. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res. 2007;13:1961-70. (Pubitemid 46649861)
34. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-45. (Pubitemid 46909922)
35. Hoetjes NJ, van Velden FH, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging. 2010;37:1679-87.
36. Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006;12:97-106. (Pubitemid 43166182)
37. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29:1639-47.
38. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with F-18 fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-44.
39. Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med. 2005;46:424-8. (Pubitemid 43093150)